Micro-cap biotech Ocular Therapeutix Inc (NASDAQ: OCUL) announced Friday that it received FDA approval for an expanded indication for its eye pain drug.
What You Need to Know
Ocular said the FDA approved its sNDA to expand the usage of Dextenza to include the treatment of ocular inflammation following ophthalmic surgery.
With the approval for the additional indication, Dextenza is now approved for the treatment of both ocular inflammation and pain following ophthalmic surgery.
The FDA had approved the drug for eye pain in November.
Dextenza is a corticosteroid and is inserted into the lower lacrimal punctum in canaliculus by the physician following ophthalmic surgery.
A single dose of the drug releases 0.4mg of dexamethasone for up to 30 days following insertion.
The FDA communicated its acceptance of the sNDA on April 2, with the PDUFA date set for Nov. 10. The approval came about five months ahead of the scheduled date.
Ocular is also evaluating Dextenza in a Phase 3 trial for allergic conjunctivitis.
"With our C-Code and pass-through payment status effective on July 1, the expanded indication gives us tremendous momentum as we approach our commercial launch," CEO Antony Mattessich said in a statement.
At last check, Ocular shares were up 5.65% at $4.36.
The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
What's Pushing Nano-Cap Biotech DiaMedica's Shares Higher?
See more from Benzinga
- The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study
- The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.